Laboratorio de Biología Integrativa (LIBi), Centro de Excelencia en Medicina Traslacional-Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de la Frontera, Temuco, Chile.
Laboratorio de Inmunidad Innata, Programa de Inmunología, ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Chile.
Front Immunol. 2020 May 15;11:901. doi: 10.3389/fimmu.2020.00901. eCollection 2020.
Cancer is a significant medical issue, being one of the main causes of mortality around the world. The therapies for this pathology depend on the stage in which the cancer is found, but it is usually diagnosed at an advanced stage in which the treatment is chemotherapy. Platinum drugs are among the most commonly used in therapy, unfortunately, one of the main obstacles to this treatment is the development of chemoresistance, which is the ability of cancer cells to evade the effects of drugs. Although some molecular mechanisms involved in resistance to platinum drugs are described, elucidation is still required of others. Secretion of inflammatory mediators such as cytokines and chemokines, by tumor microenvironment components or tumor cells, show direct influence on proliferation, metastasis and progression of cancer and are related to chemoresistance and poor prognosis. In this review, the general mechanisms associated with resistance to platinum drugs, inflammation on cancer development and chemoresistance in various types of cancer will be approached with special emphasis on the current history of CC chemokines subfamily-mediated chemoresistance.
癌症是一个重大的医学问题，是全球主要死亡原因之一。这种疾病的治疗方法取决于癌症发现的阶段，但通常在癌症已经进入晚期，治疗方法是化疗时才被诊断出来。铂类药物是治疗中最常用的药物之一，但不幸的是，这种治疗方法的主要障碍之一是产生化疗耐药性，即癌细胞逃避药物作用的能力。虽然已经描述了一些与铂类药物耐药性相关的分子机制，但仍需要阐明其他机制。肿瘤微环境成分或肿瘤细胞分泌的炎症介质，如细胞因子和趋化因子，直接影响癌症的增殖、转移和进展，并与化疗耐药性和预后不良有关。在这篇综述中，将探讨与铂类药物耐药性相关的一般机制、癌症发展中的炎症以及各种癌症中的化疗耐药性，特别强调 CC 趋化因子亚家族介导的化疗耐药性的最新研究进展。
